Cancer News and Research

Latest Cancer News and Research

NanoString to launch 3 new products for nCounter Analysis System at AACR 2012

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced that it will launch three new products for the nCounter Analysis System at the American Association of Cancer Research (AACR) Annual Meeting 2012, March 31-April 4, in Chicago, Ill.

From NanoString Technologies 31 Mar 2012

State of Texas awards Asuragen $6.8M to pursue Next Generation Sequencing applications

Asuragen, Inc. announced today that the Company received notice of a $6.8 million commercialization award to pursue Next Generation Sequencing (NGS) applications from the State of Texas through the Cancer Prevention and Research Institute of Texas ("CPRIT").

31 Mar 2012

UH clinical trial to evaluate stool DNA testing for colon cancer

In a first-of-its-kind clinical trial, physician-scientists at University Hospitals (UH) Case Medical Center's Seidman Cancer Center and Case Western Reserve University School of Medicine are studying a promising new non-invasive technology for colon cancer screening. The four-year study is recruiting patients to compare the effectiveness of stool DNA (SDNA) testing with colonoscopy for detecting large colon polyps.

31 Mar 2012

Galectin Therapeutics fourth quarter net loss increases to $3.7 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2011.

31 Mar 2012

Canadian regulatory body recommendation brings melanoma patients closer to life-extending drugs

The Melanoma Network of Canada is pleased that the Canadian regulatory body, pCODR (pan-Canadian Oncology Drug Review) has made an initial recommendation that includes positive clinical evaluations for the latest treatments for metastatic melanoma.

31 Mar 2012

Cambridge Heart fourth quarter total revenue decreases to $557,000

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today reported results for its fourth quarter and full year ended December 31, 2011. Full financial statements and corresponding commentary can be found in the Company's Form 10-K, which will be filed with the Securities and Exchange Commission on March 30, 2012.

31 Mar 2012

Number of kidney cancer cases rises over 9,000 in Great Britain

The number of cases of kidney cancer diagnosed each year in Great Britain has risen over 9,000 for the first time, new figures from Cancer Research UK show today.

31 Mar 2012

Accuray, University of Heidelberg enter multi-year master research and collaboration agreement

Accuray Incorporated, the premier radiation oncology company, announced today the signing of a multi-year master research and collaboration agreement with the University of Heidelberg, a luminary research institution located in Heidelberg, Germany that contributes to the city's top international position in therapy, research and science.

31 Mar 2012

Abbott receives CE Marking for PLEX-ID instrument and assays

Abbott announced today it has obtained CE Marking (Conformite Europeene) in the European Union to market its rapid, high-throughput PLEX-ID instrument, along with three assays for use on the system: PLEX-ID Viral IC Spectrum, PLEX-ID BAC Spectrum BC and PLEX-ID Flu.

31 Mar 2012

Differentiating between sneezing due to cold and allergies

One of the problems that parents may have during the springtime is deciphering whether their children's sneezing is due to a cold or allergies.

31 Mar 2012

Mirada Medical, BioClinica partner to extend oncology clinical trials

BioClinica, Inc., a global provider of clinical trial management solutions, today announced a partnership with Mirada Medical, a leading provider of medical image analysis software. BioClinica will integrate Mirada's XD3 software solution into its imaging core lab technology to further enhance its PET capabilities and expertise for molecular imaging trials.

From Clario 31 Mar 2012

ImmunoGen commences IMGN901 Phase II evaluation for SCLC

ImmunoGen, Inc. today announced that it has initiated Phase II testing of its IMGN901 product candidate for first-line treatment of SCLC.

31 Mar 2012

FDA approves Roche's cobas p 630 pre-analytical instrument

Roche announced today the FDA approval of a new pre-analytical instrument that provides an integrated primary tube handling solution for its widely adopted automated molecular testing platform.

31 Mar 2012

Bionovo 2011 total revenues decrease to $0.3 million

Bionovo, Inc., a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, today announced financial results for the year ended December 31, 2011.

31 Mar 2012

Cancer patients with CDI may benefit from DIFICLIR drug

New data presented at the 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) demonstrate that in cancer patients with CDI, DIFICLIR(fidaxomicin) may offer significant benefits in terms of clinical cure, recurrence and sustained clinical cure.

31 Mar 2012

ChemoCentryx fourth quarter revenues increase to $26.1 million

ChemoCentryx, Inc. announced today its financial results for the fourth quarter and year ended December 31, 2011.

31 Mar 2012

IPS reports on research study examining knowledge, beliefs of cervical cancer among Argentinian women

Inter Press Service reports on a research study conducted in Argentina that "explored women's knowledge and beliefs about cervical cancer, in the provinces with the highest mortality from this highly preventable form of cancer, to design more effective policies."

31 Mar 2012

Unapproved, misbranded drug products seized in Missouri

Dara Corrigan, associate commissioner for regulatory affairs for the U.S. Food and Drug Administration, and David M. Ketchmark, Acting U.S. Attorney for the Western District of Missouri, announced today that U.S. Marshals have seized drugs being held by Notions-n-Things Distribution of Bogard, Mo. Yesterday's seizure follows a civil forfeiture complaint that was filed in the U.S. District Court in Kansas City, Mo.

30 Mar 2012

CINJ experts available for discussion on cancer

April marks National Cancer Control Month, which focuses on the importance of prevention, treatment and research in the fight against cancer.

30 Mar 2012

BPA shows tangible effects on health endpoints at high dosage levels

Endocrine-disrupting chemicals (EDCs)-such as BPA-can show tangible effects on health endpoints at high dosage levels, yet those effects do not predict how EDCs will affect the endocrine system at low doses, according to a recent study accepted for publication in The Endocrine Society's Endocrine Reviews.

30 Mar 2012